Addiction medicine has historically operated substance by substance - a patch for nicotine, methadone for opioids, naltrexone for alcohol. No single medication has ever worked across all of them. That may be changing.

The study behind the headlines

On March 4, 2026, researchers at Washington University School of Medicine in St. Louis published findings in The BMJ that addiction specialists described as unlike anything seen in their field. The team, led by Dr. Ziyad Al-Aly, analysed electronic health records from 606,434 U.S. veterans with type 2 diabetes - all of whom were treated with either GLP-1 receptor agonists (semaglutide, liraglutide, or dulaglutide) or SGLT-2 inhibitors (a different class of diabetes drug).

The study divided participants into two groups: those without any pre-existing substance use disorder (524,817 people) and those already living with one (81,617 people). Both groups were followed for up to three years.

The results were consistent and striking across every substance studied. Al-Aly put it plainly: "The revelation about GLP-1 medication is that it really works against all major substances, and it works uniformly - not because it acts against alcohol or opioids or nicotine specifically, but because it is likely acting against the craving itself."

The substance-by-substance breakdown

For participants without a pre-existing substance use disorder - meaning GLP-1 medications may have prevented new addictions from developing - the risk reductions compared to those on SGLT-2 inhibitors were:

  • Opioids: 25% lower risk of developing opioid use disorder
  • Cocaine: 20% lower risk
  • Nicotine: 20% lower risk
  • Alcohol: 18% lower risk
  • Cannabis: 14% lower risk
  • Any substance use disorder: 14% lower risk overall

Translated into population terms: 7 fewer people per 1,000 GLP-1 users developed a new substance use disorder over the study period.

For participants who already had a substance use disorder, GLP-1 medications were associated with substantial reductions in harm:

  • 50% fewer drug-related deaths
  • 40% fewer overdose events
  • 30% fewer addiction-related emergency department visits
  • 25% fewer addiction-related hospitalisations
  • 25% fewer suicidal ideation events or attempts

In population terms: 12 fewer serious harm events per 1,000 GLP-1 users with existing substance use disorders.

Why these numbers are significant in context

To appreciate why addiction researchers reacted so strongly, consider what currently exists for each substance:

Opioids: Methadone and buprenorphine are the gold-standard medications for opioid use disorder. Both are highly effective - but both carry their own dependency profiles, require specialist prescribing, and do nothing for other substances. A 25% reduction in opioid use disorder risk from a medication already being taken for an unrelated condition is a clinically meaningful add-on benefit.

Alcohol: Naltrexone and acamprosate are the main FDA-approved options. Both have modest effect sizes in real-world settings. An 18% risk reduction observed in a real-world population of 600,000 people compares favourably.

Nicotine: Varenicline (Chantix) remains the most effective pharmacotherapy for smoking cessation. A 20% reduction in nicotine use disorder risk from a weekly injection taken for weight or diabetes is a significant co-benefit - particularly for patients who have tried and failed with dedicated cessation aids.

Cocaine and methamphetamine: There are currently no FDA-approved medications for cocaine or methamphetamine use disorder. The 20% reduction in cocaine use disorder risk in this study represents the first large-scale signal that a pharmacological intervention may have preventive benefit for stimulant addiction - a category where clinicians have had essentially no tools.

What "acting on the craving itself" means biologically

The mechanism hypothesis is centred on GLP-1 receptors in the brain. These receptors are not just in the gut and pancreas - they concentrate in the nucleus accumbens, the ventral tegmental area, the prefrontal cortex, and the amygdala. These are the structures that process reward, regulate impulse control, and encode the emotional memory of pleasurable experiences.

When addictive substances trigger dopamine release in these regions, the brain records a powerful reward signal. Over repeated exposure, those signals build into cravings - involuntary urges that persist long after the last use. GLP-1 receptor activation appears to dampen dopamine signalling in these reward circuits, reducing the intensity of cravings without targeting any specific substance.

Al-Aly calls this quieting "drug noise" - analogous to how GLP-1 medications quiet "food noise" in people with obesity. Patients on Wegovy or Ozempic often describe a sudden absence of preoccupation with food. The same neural quieting, the hypothesis goes, extends to other reward-seeking compulsions driven by the same circuitry.

The limits of what this study tells us

Observational studies - even very large ones - cannot establish causation with certainty. This analysis compared GLP-1 users to SGLT-2 users in a veteran population that skews older and male. Whether the same effects appear in women, younger adults, and people without diabetes requires dedicated clinical trials.

The investigators are clear that GLP-1 medications should not yet be considered first-line addiction treatments. The key questions still unanswered include:

  • Do the benefits disappear when the medication is stopped?
  • Do cravings return more intensely after discontinuation - the same rebound pattern seen with appetite?
  • What dose is needed to produce meaningful effects on addiction specifically?
  • How do GLP-1 side effects interact with withdrawal symptoms or mood instability common in addiction recovery?

More than a dozen clinical trials are now actively enrolling to answer these questions. One trial has already added weekly semaglutide to cognitive behavioural therapy for alcohol use disorder and reported that the combination further reduced heavy drinking beyond what therapy alone achieved - the first controlled evidence of the effect in that setting.

What this means for people currently on GLP-1 medications

If you are taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) and you drink alcohol or smoke, this research has direct relevance. The reduction in desire for alcohol and nicotine that many GLP-1 users report anecdotally now has a large-scale dataset behind it. It is a real pharmacological effect, not placebo or coincidence.

It also points to a practical consideration: if GLP-1 medications are quietly reducing your alcohol intake alongside their primary effects, stopping them abruptly could change more than just your appetite. Having a clear plan for discontinuation - and discussing it with your prescribing doctor - matters more than many patients realise.

One important nutritional note: significant reductions in food intake on GLP-1 medications can deplete B vitamins, vitamin D, iron, and magnesium - nutrients that directly affect mood, energy, and neurological function. Maintaining adequate levels of these micronutrients supports the brain chemistry underpinning both well-being and impulse regulation. The GLP-1 Shield supplement formulation was built specifically to address these gaps in people on GLP-1 therapy.

Worried about your own nutrient gaps on GLP-1?

Be among the first to try the scientifically designed GLP-1 Shield supplements.

Frequently asked questions

Which GLP-1 drug was studied for addiction in the BMJ 2026 paper?
The study analysed three GLP-1 receptor agonists: semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity). The results were reported across the GLP-1 class as a whole, not broken down by individual drug. Semaglutide is the most commonly used of the three in current clinical practice.
Can GLP-1 drugs help with opioid addiction?
The 2026 BMJ study found a 25% lower risk of developing opioid use disorder in GLP-1 users compared to those on SGLT-2 inhibitors, and a 40% reduction in overdose events in those already struggling with opioid addiction. These are preliminary findings from an observational study - GLP-1 drugs are not approved for opioid use disorder treatment and should not replace existing medications like buprenorphine.
Does tirzepatide also reduce addiction cravings, or only semaglutide?
The BMJ study examined semaglutide, liraglutide, and dulaglutide - not tirzepatide (Mounjaro, Zepbound). However, tirzepatide activates GLP-1 receptors in the same brain regions, and researchers expect the craving-reduction effect to be present. Dedicated studies on tirzepatide and addiction are not yet published.
Are there clinical trials testing GLP-1 medications for addiction treatment?
Yes - as of early 2026, more than a dozen trials are underway or enrolling, testing GLP-1 medications specifically for alcohol, nicotine, opioid, and stimulant use disorders. One completed trial showed semaglutide added to cognitive behavioural therapy further reduced heavy drinking beyond therapy alone. Results from larger trials are expected over the next two to three years.